<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02566681</url>
  </required_header>
  <id_info>
    <org_study_id>MSC/ONM</org_study_id>
    <secondary_id>2012-005813-38</secondary_id>
    <nct_id>NCT02566681</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Use of Autologous Bone Marrow Stem Cells Seeded on Porous Tricalcium Phosphate Matrix and Demineralized Bone Matrix in Patients With Osteonecrosis</brief_title>
  <acronym>MSC/ONM</acronym>
  <official_title>Phase I Clinical Trial of Use of Autologous Bone Marrow Stem Cells Seeded on Porous Tricalcium Phosphate Matrix and Demineralized Bone Matrix in Patients With Osteonecrosis (MSC/ONM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Red de Terapia Celular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitario Virgen de la Arrixaca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spanish National Health System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Public Health Service, Murcia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Red de Terapia Celular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of use of autologous bone marrow stem
      cells seeded on porous tricalcium phosphate matrix and demineralized bone matrix in patients
      with osteonecrosis of the jaw by a prospective, single-center, open, nonrandomized and
      unblinded clinical trial.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of serious adverse events related to the procedure.</measure>
    <time_frame>24 months from baseline</time_frame>
    <description>Apparition of Bone ischemic events. Neoformations.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of non-serious adverse events related to the procedure.</measure>
    <time_frame>24 months from baseline</time_frame>
    <description>Local infection of the surgical wound. Pseudarthrosis implant. Allergic reactions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Repair the injury</measure>
    <time_frame>24 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local pain assessed by visual analog scale</measure>
    <time_frame>24 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone formation, measured by Computed tomography (mm)</measure>
    <time_frame>24 months from baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life, measured by EuroQol-5D.</measure>
    <time_frame>24 months from baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Osteonecrosis of Jaw</condition>
  <arm_group>
    <arm_group_label>MSC construct for Osteonecrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with definite diagnosis of osteonecrosis of the jaw by clinical and radiological examination of any etiology will receive a construct made of Bone Marrow Stem Cell + Tricalcium Phosphate + Demineralized Bone Matrix (MSC+TP+DBM).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MSC construct for Osteonecrosis</intervention_name>
    <description>30 days before implanting the construct made with MSC + TP + DBM, bone marrow of patients diagnosed with osteonecrosis of the jaw included in the clinical trial is obtained. The bone marrow will be obtained according to standard practice for Hematologists of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).
Mononuclear bone marrow cells were separated and cultured in GMP conditions (Good Manufacturing Practices). The cells are seeded on tricalcium phosphate and maintained in culture for 14 days.
The day when the implant is performed, the patient is prepared in the operating room. The area where the implant will be placed is cleaned. Mesenchymal cells seeded in tricalcium phosphate are mixed with demineralized bone matrix and It's coagulated with autologous platelet rich plasma and grafting is performed. Finally, the oral mucosa or skin will be sealingly closed by silk sutures.</description>
    <arm_group_label>MSC construct for Osteonecrosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of mandibular osteonecrosis of any etiology defined by clinical and
             radiological examination.

          -  Bone defect anteroposterior dimension less than or equal to 4 cm in the mandible or
             the maxilla 2.5, and / or bone bed sufficient to ensure the integrity of the construct
             during surgery.

          -  No response to conservative treatment.

          -  Provide sufficient assurance of adherence to protocol.

          -  Provide written consent

          -  Meet all the inclusion criteria

        Exclusion Criteria:

          -  Concomitant psychiatric illness.

          -  Uncontrolled concomitant systemic disease.

          -  Active infectious disease in the focus of mandibular osteonecrosis.

          -  Neoplastic disease in complete remission less than 2 years.

          -  Pregnant patients.

          -  Patients with active feeding.

          -  Patients physically fertile, defined as all women physiologically capable of becoming
             pregnant, UNLESS they are using reliable methods of contraception.

          -  Patients with cardiac disease, renal, hepatic, systemic, immune that may influence
             patient survival during the test.

          -  Inclusion in other clinical trials in active treatment.

          -  Inability to understand the informed consent.

          -  You need not meet any exclusion criteria
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Victor Villanueva San Vicente, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Virgen de la Arrixaca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco J Rodríguez Lozano, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad de Murcia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natalia García Iniesta</last_name>
    <phone>+34968381221</phone>
    <email>nagarini@yahoo.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clínico Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalia García Iniesta</last_name>
      <phone>+34968381221</phone>
      <email>nagarini@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Victor Villanueva San Vicente, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisco J Rodríguez Lozano, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>María A Rodríguez González, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Segarra Fenoll, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María M Gonzálvez García, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>José M Moraleda Jiménez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel Blanquer Blanquer, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana M García Hernández, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joaquín A Gómez Espuch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>María Dolores López Lucas, Graduate</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Darío Sánchez Salinas, Graduate</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisca Iniesta Martínez, Graduate</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carmen Algueró Martín, Graduate</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Francisca Velázquez Marín, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ricardo Oñate Sánchez, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Luis Meseguer Olmo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2015</study_first_submitted>
  <study_first_submitted_qc>September 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2015</study_first_posted>
  <last_update_submitted>March 29, 2017</last_update_submitted>
  <last_update_submitted_qc>March 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteonecrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

